home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9408e.zip
/
M9480839.TXT
< prev
next >
Wrap
Text File
|
1994-09-05
|
2KB
|
38 lines
Document 0839
DOCN M9480839
TI Screening a low prevalence population for HIV-2 using a combination
HIV-1/HIV-2 enzyme immunoassay and an immunofluorescence assay.
DT 9410
AU Zanto SN; Treichel LJ; Abbott DO; Montana Public Health Laboratory,
Helena.
SO Abstr Gen Meet Am Soc Microbiol. 1994;94:554 (abstract no. C-361).
Unique Identifier : AIDSLINE ASM94/94313106
AB The Montana Public Health Laboratory has conducted screening for HIV-1
since 1985, with an estimated prevalence of HIV infection of 0.06%. To
evaluate test performance and to determine the feasibility of
incorporating screening for HIV-2, 2000 random serum specimens received
for routine screening were tested using both Genetic Systems HIV-1/HIV-2
EIA and Viral Testing Systems Fluorognost HIV-2 IFA kits. Of the 2000
specimens screened, 1949 specimens were negative in both the EIA and IFA
test systems. Three specimens were repeatedly reactive by EIA, and
negative by IFA. One specimen was positive in both the EIA and IFA test
systems. Forty-seven (47) specimens were EIA non-reactive and IFA
repeatedly indeterminate. In order to resolve HIV antibody status of the
reactive serum specimens, additional testing was necessary on 4 of 2000
EIA specimens, and 48 of 2000 IFA specimens. The present HIV-2 IFA kit
appears better suited for supplemental HIV-2 testing rather than
screening low prevalence populations. The incorporation of routine HIV-2
screening into the HIV testing algorithms of low prevalence populations,
although feasible, may not be an appropriate use of limited public
health resources.
DE Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL Comparative
Study Fluorescent Antibody Technique Human HIV Antibodies/*BLOOD HIV
Seronegativity HIV Seropositivity *HIV Seroprevalence HIV-1/ISOLATION
& PURIF HIV-2/*ISOLATION & PURIF Immunoenzyme Techniques Mass
Screening Montana/EPIDEMIOLOGY Random Allocation Reagent Kits,
Diagnostic MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).